Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome.
Wong F, Pappas SC, Curry MP, Reddy KR, Rubin RA, Porayko MK, Gonzalez SA, Mumtaz K, Lim N, Simonetto DA, Sharma P, Sanyal AJ, Mayo MJ, Frederick RT, Escalante S, Jamil K; CONFIRM Study Investigators.
N Engl J Med. 2021 Mar 4;384(9):818-828. doi: 10.1056/NEJMoa2008290.
Pathophysiology of Hepatorenal Syndrome.
Velez JCQ, Latt N, Rodby RA.
Adv Kidney Dis Health. 2024 Mar;31(2):87-99. doi: 10.1053/j.akdh.2024.01.002.
News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document.
Angeli P, Garcia-Tsao G, Nadim MK, Parikh CR.
J Hepatol. 2019 Oct;71(4):811-822. doi: 10.1016/j.jhep.2019.07.002. Epub 2019 Jul 11.
Evidence-based clinical practice guidelines for Liver Cirrhosis 2020.
Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K.
J Gastroenterol. 2021 Jul;56(7):593-619. doi: 10.1007/s00535-021-01788-x. Epub 2021 Jul 7.
Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy.
Iwakiri Y, Trebicka J.
JHEP Rep. 2021 Jun 4;3(4):100316. doi: 10.1016/j.jhepr.2021.100316. eCollection 2021 Aug.
Hepatorenal syndrome and type 1 and 2 cardiorenal syndromes: distinct competing medical therapies applied to a similar background of vasomotor reactive nephropathy.
De Vecchis R, Esposito C, Di Biase G, Ariano C.
Minerva Cardioangiol. 2014 Feb;62(1):105-16.
Hepatorenal syndrome.
Angeli P, Morando F, Cavallin M, Piano S.
Contrib Nephrol. 2011;174:46-55. doi: 10.1159/000329235. Epub 2011 Sep 9.
Is type 2 hepatorenal syndrome still a potential indication for treatment with terlipressin and albumin?
Angeli P, Piano S.
Liver Transpl. 2015 Nov;21(11):1335-7. doi: 10.1002/lt.24339.
Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2.
Nguyen-Tat M, Jäger J, Rey JW, Nagel M, Labenz C, Wörns MA, Galle PR, Marquardt JU.
United European Gastroenterol J. 2019 May;7(4):529-537. doi: 10.1177/2050640619825719. Epub 2019 Feb 20.
Hepatorenal Syndrome Type 1: From Diagnosis Ascertainment to Goal-Oriented Pharmacologic Therapy.
Velez JCQ.
Kidney360. 2021 Dec 3;3(2):382-395. doi: 10.34067/KID.0006722021. eCollection 2022 Feb 24.
